Drug Profile
ASP 8374
Alternative Names: ASP-8374; PTZ-201Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Potenza Therapeutics
- Developer Astellas Pharma; Potenza Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 20 Apr 2022 Astellas Pharma completes a phase I trial in Solid tumours (Combination therapy, Monotherapy, Inoperable/unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Canada, Italy, Japan, Portugal, Spain, South Korea, Taiwan and United Kingdom (IV) (NCT03260322)
- 06 Apr 2021 Dana-Farber Cancer Institute in collaboration with Astellas Pharma and Regeneron Pharmaceuticals plans a phase I trial in Glioma (Metastatic disease, Late-stage disease, Recurrent, Combination therapy, Second-line therapy or greater) in USA (IV, Infusion) in September 2021 (NCT04826393)
- 09 Dec 2020 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV) (Astellas Pharma pipeline, December 2020)